-
Innovation Ranking
NewInnovation Ranking – Ascendis Pharma AS
Ascendis Pharma AS (Ascendis Pharma) is a biopharmaceutical company that focuses on developing drugs for endocrinology and oncology indications. It is investigating TransCon hGH, a long-acting human growth hormone prodrug targeting GHD (growth hormone deficiency); TransCon PTH drug to treat hypoparathyroidism by restoring physiologic levels of PTH (parathyroid hormone); and TransCon CNP, a CNP (C-type natriuretic peptide) drug against achondroplasia (ACH). It is also evaluating TransCon TLR (toll-like receptor) 7/8 agonist, and TransCon IL-2 β/γ, an interleukin-2 variant that activates...
-
Product Insights
NewNet Present Value Model: Ascendis Pharma AS’s TransCon CNP
Empower your strategies with our Net Present Value Model: Ascendis Pharma AS's TransCon CNP report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tebotelimab in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tebotelimab in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tebotelimab in Diffuse Large B-Cell Lymphoma Drug Details: Tebotelimab (MGD-013)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Navepegritide in Achondroplasia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Navepegritide in Achondroplasia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Navepegritide in Achondroplasia Drug Details: Navepegritide (TransCon CNP) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TransCon IL-2 Beta/Gamma in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TransCon IL-2 Beta/Gamma in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TransCon IL-2 Beta/Gamma in Cervical Cancer Drug Details: Recombinant...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TransCon IL-2 Beta/Gamma in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TransCon IL-2 Beta/Gamma in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TransCon IL-2 Beta/Gamma in Melanoma Drug Details: Recombinant Protein is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TransCon IL-2 Beta/Gamma in Human Papillomavirus (HPV) Associated Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TransCon IL-2 Beta/Gamma in Human Papillomavirus (HPV) Associated Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TransCon IL-2 Beta/Gamma in Human Papillomavirus...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palopegteriparatide in Hypoparathyroidism
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palopegteriparatide in Hypoparathyroidism report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palopegteriparatide in Hypoparathyroidism Drug Details: Palopegteriparatide (Yorvipath) is a parathyroid hormone (PTH) replacement therapy. Yorvipath...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TransCon IL-2 Beta/Gamma in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TransCon IL-2 Beta/Gamma in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TransCon IL-2 Beta/Gamma in Solid Tumor Drug Details: Recombinant...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TransCon IL-2 Beta/Gamma in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TransCon IL-2 Beta/Gamma in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TransCon IL-2 Beta/Gamma in Renal Cell Carcinoma Drug...